《中国支气管哮喘防治指南(2020年版)》评述  

Review of guidelines for bronchial asthma prevent and management(2020 edition)

作　　者：王导新[1] 熊伟 王勤[1] 朱涛[1] WANG Daoxin;XIONG Wei;WANG Qin;ZHU Tao(Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China)

机构地区：[1]重庆医科大学附属第二医院呼吸内科,重庆404000

出　　处：《西部医学》2022年第1期1-4,共4页Medical Journal of West China

基　　金：国家自然科学基金青年项目(8180011074);重庆市科卫联合医学科研项目(面上项目)(2020MSXM112)。

摘　　要：支气管哮喘(哮喘)是临床最常见的慢性呼吸系统疾病之一,具有发病隐匿,临床表现多样的特点,同时由于部分患者缺乏典型症状,在临床实践中易出现漏诊和误诊情况。另一方面,我国哮喘患者整体控制率仍处于较低水平。为了促进基层哮喘防治体系建设,进一步增强临床医生尤其是基层医生对哮喘的诊疗能力,本文将从临床实践出发,根据《中国支气管哮喘防治指南(2020年修订版)》更新内容,对哮喘管理部分尤其是哮喘的特征及治疗等关键问题进行评述,以供临床参阅与借鉴。Bronchial asthma(Asthma)is one of most common chronic pulmonary diseases.Meanwhile,asthma is a heterogeneous disease with the features of occult onset and variable presentations.Due to lack of classic clinical manifestations in part of asthma patients,misdiagnosis and miss-diagnosis were happened from time to time.Additionally,the overall asthma control status is still not very optimistic in China.Then,in order to improve the asthma management system in primary medical institutions and the ability of asthma treatment in primary physicians,the review is to interpret some key issues in asthma management,which is based on“Guidelines for bronchial asthma prevent and management(2020 edition)Asthma group of Chinese Thoracic Society”.

关 键 词：哮喘管理 非典型哮喘 重度哮喘 哮喘治疗 哮喘患病率 

分 类 号：R562.25[医药卫生—呼吸系统]